SK Biopharm Signs 4.3 Billion KRW Pharmaceutical Supply Contract
[Asia Economy Reporter Lee Seon-ae] SK Biopharm announced on the 30th that it has signed a contract to supply pharmaceuticals worth 4,315,570,000 KRW by the end of next year. The contract is to supply finished pharmaceuticals and raw materials under the technology transfer agreement signed with Arvelle Therapeutics for the European sales of SK Biopharm's new epilepsy treatment drug Cenobamate. The contract amount corresponds to 16.60% of sales.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Greater Impact on Women Than Men"... The 'Diet Trap' That Causes Sleepless Nights and Suffering
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
